PTPRC and neoplasm: We confirmed these findings by flow cytometry, demonstrating that BAMBI decreased in tumor-infiltrating mMDSCs (Figure 1, D and E), but remained unchanged in other immune cells or CD45– cells, including tumor cells (Supplemental Figure 3, A and B).